Advances in Targeting HPV Infection as Potential Alternative Prophylactic Means by Carse, Sinead et al.
 International Journal of 
Molecular Sciences
Review
Advances in Targeting HPV Infection as Potential Alternative
Prophylactic Means
Sinead Carse 1,2,3, Martina Bergant 4 and Georgia Schäfer 1,2,3,*


Citation: Carse, S.; Bergant, M.;
Schäfer, G. Advances in Targeting
HPV Infection as Potential
Alternative Prophylactic Means. Int. J.
Mol. Sci. 2021, 22, 2201. https://
doi.org/10.3390/ijms22042201
Academic Editor: Marta del Pino
Received: 3 February 2021
Accepted: 19 February 2021
Published: 23 February 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town,
Observatory 7925, South Africa; crssin001@myuct.ac.za
2 Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences,
University of Cape Town, Observatory 7925, South Africa
3 Division of Medical Biochemistry and Structural Biology, Department of Integrative Biomedical Sciences,
Faculty of Health Sciences, University of Cape Town, Observatory 7925, South Africa
4 Laboratory for Environmental and Life Sciences, University of Nova Gorica, Vipavska 13,
5000 Nova Gorica, Slovenia; martina.bergant@ung.si
* Correspondence: georgia.schafer@icgeb.org; Tel.: +27-21-4047630
Abstract: Infection by oncogenic human papillomavirus (HPV) is the primary cause of cervical
cancer and other anogenital cancers. The majority of cervical cancer cases occur in low- and middle-
income countries (LMIC). Concurrent infection with Human Immunodeficiency Virus (HIV) further
increases the risk of HPV infection and exacerbates disease onset and progression. Highly effective
prophylactic vaccines do exist to combat HPV infection with the most common oncogenic types, but
the accessibility to these in LMIC is severely limited due to cost, difficulties in accessing the target
population, cultural issues, and maintenance of a cold chain. Alternative preventive measures against
HPV infection that are more accessible and affordable are therefore also needed to control cervical
cancer risk. There are several efforts in identifying such alternative prophylactics which target key
molecules involved in early HPV infection events. This review summarizes the current knowledge
of the initial steps in HPV infection, from host cell-surface engagement to cellular trafficking of the
viral genome before arrival in the nucleus. The key molecules that can be potentially targeted are
highlighted, and a discussion on their applicability as alternative preventive means against HPV
infection, with a focus on LMIC, is presented.
Keywords: human papillomavirus (HPV); cervical cancer; low- and middle- income countries
(LMIC); prophylactic vaccines
1. Introduction
Papillomaviruses (PVs) are small, non-enveloped, double stranded DNA viruses
belonging to the highly diverse family of Papillomaviridae [1,2]. Over 200 types of human
papillomaviruses (HPVs) alone have been characterized [3] and are classified as either
high-risk or low-risk, depending on their ability to cause malignancy [1]. HPVs infect the
skin and mucosal epithelial cells, causing hyper-proliferative lesions. Mucosal HPV types
are highly prevalent and are transmitted through sexual activity. This leads to a significant
disease burden on a global scale as persistent infection with high-risk (oncogenic) HPVs
are associated with 5% of all human cancers. Of those, the most common HPV-associated
malignancy is cervical cancer with virtually all cases linked to an underlying oncogenic
HPV infection [4,5]. Over 20 oncogenic HPV types have been identified and characterized,
out of which HPV16 and 18 are the most common types in the world and contribute to 70%
of all documented cases [4,6]. Low-risk HPV types, such as HPV6 and 11, do not cause
cancer. However, infection with these HPV types can result in the manifestation of benign
lesions and warts of the anogenital areas [7]. Moreover, perinatally acquired HPV6 and 11
can cause recurrent respiratory papillomatosis in infants and young children [7].
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Cervical cancer is more prevalent in low-and middle-income countries (LMIC), ac-
counting for more than 80% of the global disease burden [8]. World-wide, cervical cancer
ranks fourth for both incidence and mortality in women [9]. However, it is the second
most common cancer in South Africa [9,10] as well as the leading cause of female cancer-
associated deaths in Sub-Saharan Africa [11]. The higher incidence of HPV and cervical
cancer in LMIC has not least been attributed to the Human Immunodeficiency Virus
(HIV)/acquired immunodeficiency syndrome (AIDS) epidemic in these regions [12], and
in fact, cervical cancer is considered an AIDS-defining malignancy [13].
As infection with oncogenic HPVs is almost always the cause of cervical cancer,
it is potentially an entirely preventable condition. However, the current therapies aim
to remove lesions and abnormal cells rather than targeting the HPV infection as the
causative agent [14]. To date, no direct anti-HPV treatment is available. However, three
highly efficacious prophylactic vaccines exist against the most common high-risk HPV
types [15–17]. All three vaccines provide protection against HPV16 and 18, with Gardasil-9
(Merck) additionally protecting against new infection with the oncogenic types 31, 33,
45, 52, and 58 [16]. However, the vaccines do not provide treatment for individuals who
are already infected with HPV. Since all three HPV vaccines are composed of virus-like
particles (VLPs) derived from the spontaneous assembly of individual type-specific L1
capsid proteins [18], they provide little to no cross-protection against other HPV types that
are not included in the vaccines as the immune response is highly type specific. This means
that women remain exposed to high-risk HPVs that are not covered by these vaccines
and develop low- and high-grade cervical intraepithelial lesions [19]. A concerning and
unexplained phenomenon is also that women vaccinated with first-generation (bivalent
and quadrivalent) HPV vaccines are at higher risk of contracting non-HPV 16/18 high-risk
HPV types than unvaccinated women [20].
Although the South African Department of Health began a vaccination program and
rolled out Cervarix™ to school girls (who are approximately 9 years of age) in 2014 [10],
vaccinations are unlikely to alleviate the burden of HPV-related diseases in the near future.
The need to receive multiple vaccination shots as well as the limited access in health care
workers reaching the designated schools are believed to be the main reasons why many
young girls are thought to have missed the opportunity to be immunized. Furthermore, the
need for a cold chain (controlled storage of the vaccine at low temperatures) has been diffi-
cult to maintain in LMICs with substandard infrastructure and low funding, which makes
administration of the vaccines to schoolgirls in rural areas even more challenging [21].
Since the current vaccination programs are limited to girls in a specific year of schooling,
a large number of young girls will not have had the opportunity to receive the vaccine
through this program, and the high costs of the vaccines limit their affordability to a high
proportion of the population [22]. This is further exacerbated by the stigma and lack of
knowledge surrounding cervical cancer, HPV infection, and HPV vaccination, as well as
reproductive health in general, as adolescent health platforms often do not exist [21,22].
Given that the disease burden resulting from persistent HPV infections is likely to
continue, alternative therapies for the treatment and prevention of HPV infections are
required, particularly ones that are more easily accessible to people in LMIC. Topical
antiviral microbicides that can block the full spectrum of genital HPV infections (as well
as other common sexually transmitted infections (STIs)) could either complement the
current vaccines, be offered to those without access to these vaccines, or even be given to
people who are already infected with HPV. In 2001, Christensen et al. noted the lack of
research into compounds with microbicidal activity against papillomaviruses [23]. The
only reagents that had been studied and shown to inhibit HPV infection were monoclonal
antibodies (MAbs) with type-specific neutralizing activity, and broad-spectrum antiviral
agents such as alkyl sulfates and monocaprin [24–27]. Over the last two decades, research
has delved into discovering and characterizing a broad spectrum of molecules with anti-
HPV activity. Many approaches are targeting the early steps of HPV infection (cell-surface
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binding, intracellular trafficking, etc.) as a promising strategy in preventing and treating
HPV infections.
This review briefly summarizes the current knowledge on the early stages of HPV
infection, from cell surface binding to intracellular trafficking, and discusses some of the
research in the discovery and development of anti-HPV molecules, with the aim to provide
an overview of alternative prophylactic means that could be potentially developed in
HPV/cervical cancer prevention strategies.
2. Early Stages of HPV Infection
In order to develop molecules that target the early steps of HPV infection, the mecha-
nisms used by HPV for internalization and successful infection must be understood. This
review will provide a brief summary of HPV entry. For more comprehensive reviews of pa-
pillomavirus cell surface binding and entry, refer to Raff et al. [28] and Day et al. [29].
For in depth reviews on papillomavirus endocytosis, refer to Siddiqa et al. [30] and
Mikuličić et al. [31].
HPV displays a rather specific target cell tropism and primarily infects the basal
keratinocytes of squamous epithelium, such as is found in the mucosal epithelial lining
of the cervix [32,33]. It is well established that epithelial wounding (or damage) is a pre-
requisite for efficient HPV infection in an in vivo setting [34–36]. It is likely that abrasions
in the outermost protective layers help the virions gain access to the mitotically-competent
basal epithelial cells in the inner layers of the epithelium, as these are the cells that are able
to establish episomal viral genome replication [34,37].
HPVs encode two capsid proteins that make up the viral structure and are essential
for host cell engagement and the early steps in infection. The major capsid protein (L1)
spontaneously assembles into a 72-pentamer icosahedral structure [38,39]. The minor
capsid protein (L2) is not essential for capsid formation but plays an important role in
successful infection [40]. A maximum occupancy of 72 L2 molecules can be incorporated
into the capsid of an HPV particle [40].
2.1. HSPG Binding at The Cell Surface
Both the major L1 capsid protein and the mainly hidden minor L2 capsid protein have
been shown to be involved in the initial binding and entry steps into the target cells of the
basal epithelium [39,41]. However, the exact mechanisms and surface receptors used by
HPV for successful entry and subsequent establishment of infection are still debated.
It is widely accepted that the initial cell surface molecules that HPVs interact with
are heparan sulphate proteoglycans (HSPGs) [34,42,43]. HSPGs are glycoproteins that
are found on the cell surface and in the extracellular matrix (Figure 1), where they in-
teract with a wide range of ligands and enhance formation of their receptor-signaling
complexes [44,45]. In mammals, syndecans and glypicans constitute the predominant cell
surface HSPGs [46,47]. HSPGs are negatively charged molecules comprising of a core
protein linked to glycosaminoglycan (GAG) chains of unbranched sulfated polysaccharides
known as heparan sulfates (HS). HS are structurally related to heparin, but heparin is more
sulfated and has a higher content of iduronic acid [48]. Many infectious pathogens and
viruses interact with HSPGs on the cell surface, or on the basement membrane, for attach-
ment and subsequent cellular entry, making it a promising target for viral inhibitors [49–56].
Specifically, the L1 capsid protein of HPV binds to the GAG chains of HSPGs [34].
Apart from HSPG binding, HPV has been proposed to bind to laminin 332 (a protein
secreted into the extracellular matrix by migrating keratinocytes) in a transient manner,
which results in uptake by proliferating keratinocytes expressing α6 integrin [57,58].
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Figure 1. Schematic illustration of the early stages of human papillomavirus (HPV) infection, indicating the sites of inhibition
of various anti-HPV molecules. Briefly: binding to heparan sulfate proteoglycans (HSPGs) results in conformational changes
of the viral capsid, which facilitates interactions between the capsid and cyclophilin B (CyPB) and cleavage by kallikrein-8
(KLK8). This results in the exposure of the L2 N-terminus, containing a conserved site which is cleaved by furin. This is
followed by dissociation of the capsid from HSPGs and exposure of a binding site in L1, potentially needed for recognition
by an unknown entry receptor complex. The viral capsid undergoes ligand induced endocytosis (which is clathrin-,
caveolin-, cholesterol- and dynamin-independent) and depends on the reorganization of the actin cytoskeleton. Membrane
protrusion of the L2 capsid protein is chaperoned by γ-secretase, which allows L2 to interact with host cell factors in the
cytosol during transport. HPVs localize with early antigen 1 (EEA10) compartments in a Rab5 GTPase-dependent manner.
The early endosome matures into the late endosome when it fuses with lysosomes. Lysosomal degradation is driven by
the formation of multivesicular bodies (MVBs). Most of the contents are degraded by lysosomal degradation, including
the majority of the L1 capsid protein. Endosomal escape and subsequent post-endocytic trafficking of high-risk HPVs is
regulated by CD63-syntenin-1-ALIX, which traffics HPV to these multivesicular endosomes. Here, the capsids disassemble
in a pH-dependent manner, and egress from the late endosome. The L2/vDNA cargo enters the TGN, where the protruding
L2 protein interacts with SNX17, SNX27 and retromer complex.
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2.2. Furin Cleavage and Subsequent Transfer to An Unknown Receptor/Receptor Complex
Binding to HSPGs induces conformational changes in the capsid and facilitates pro-
teolytic cleavage of L1 by the secreted serine-protease kallikrein-8 (KLK8) [34,59]. This
cleavage allows for interactions between the capsid and cyclophilin B, which results in
further conformational changes that exposes the L2 N-terminus (Figure 1). The exposed
N-terminus contains a conserved consensus cleavage site for the host extracellular propro-
tein convertase furin [60]. This interaction has been shown to be essential for successful
infection of HPV, as furin cleavage results in the exposure of a binding site on L1, postulated
to be recognized by an unknown receptor, or receptor complex [34,59,61]. The described
changes in virion conformation further facilitate the reduction in the binding affinity to
HSPGs, thereby facilitating the engagement with the unknown receptor(s), or receptor
complex (Figure 1) [62]. The importance of furin for successful infection was demonstrated
by using furin precleaved HPV-PsVs together with HSPG deficient cell lines: only furin
precleaved PsVs were able to infect HSPG-deficient cells, while untreated PsVs could
not [63]. These findings highlight the role of initial HSPG attachment to facilitate the critical
step of L2 cleavage by furin and association with the putative second receptor/receptor
complex for entry. Furin cleavage has also been implicated in successful endosomal escape
prior to transport of the L2/viral DNA complex to the nucleus, emphasizing the necessity
of furin cleavage for successful HPV infection [29,61].
2.3. Intracellular Trafficking and Transport of The L2/Vdna Complex to The Nucleus
After the binding of HPV to the unknown receptor/receptor complex, the capsids
undergo internalization via endocytosis [30]. The mode of HPV internalization has been
contradictorily discussed. No generalized mechanism for HPV endocytosis has been
reported, as it seems to depend on host cell and virus type [30]. More recent report describes
a novel endocytic pathway exploited by HPV16 during host cell entry. This ligand-induced
pathway is clathrin-, caveolin-, cholesterol-, and dynamin-independent and depends on
the reorganization of the actin cytoskeleton, thereby sharing many requirements with
macropinocytosis but differing in the mode of vesicle formation [64–66]. Other studies
revealed that tetraspanin CD151 and possibly other tetraspanins [67], the cytoskeletal
adaptor obscurin-like 1 (OBSL1) [65,68], and the phospholipid-binding protein annexin
A2 [31,69] are also involved in HPV16 endocytosis (Figure 1). It has been shown that
HPV16, 18, and 31 share similar requirements for entry [70], suggesting that all HPV types
of the alpha genus use this endocytosis pathway [31].
The endocytosed HPVs are sorted into early endosomes, and HPV16 and 31 have
been reported to localize with early endosome antigen 1 compartments in a Rab5 GTPase-
dependent manner [71,72]. The early endosome matures into the late endosome, when it
fuses with lysosomes [30]. Most of the contents are degraded by lysosomal degradation,
including a majority of the L1 capsid protein [64,66]. The L2/viral DNA (L2/vDNA)
complex, however, escapes the endosome for further trafficking towards the nucleus [30].
The driving force for lysosomal degradation of HPV-containing late endosomes is the
formation of multivesicular bodies (MVBs) which contain intralumenal vesicles (ILVs) [30].
The post-endocytosis trafficking of high-risk HPVs is regulated by CD63-syntenin-1-ALIX,
which has been shown to traffic HPV16, 18 and 31 to multivesicular endosomes, where the
capsids disassemble, leading to exposure and transport of the L2/vDNA complex to the
trans golgi network (TGN) [73]. Annexin A2 heterotetramer (A2t) has also been implicated
in virus progression to MVBs, where the depletion of A2t reduces capsid uncoating and an
apparent increase in lysosomal degradation of L1 [74].
Late endosome sorting and the subsequent disassembly of the HPV capsid is pH-
dependent [30,75]. Endosomal acidification assists in separating the L2/vDNA from the
L1 during capsid uncoating. However, recent studies have shown that a small amount of
intact L1 remains associated with the L2/vDNA complex and accompanies the complex to
the TGN and nucleus (Figure 1) [76].
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As previously mentioned, furin-cleaved L2 is crucial for successful HPV infection as it
is instrumental in endosomal escape. Specifically, the C-terminal cell penetration peptide
(CPP) of L2 that protrudes through the endosomal membrane initiates membrane insertion
of the viral particle, while its N-terminal putative transmembrane (TM) domain then
reaches the membrane bilayer [77–79]. γ-Secretase has been proposed as a chaperone that
interacts with the L2 TM domain to promote its membrane insertion, where the N-termiinal
region upstream of the TM remains in the lumen throughout the cellular entry process after
insertion [80]. After the L2/vDNA cargo egresses from the late endosome, it enters the
TGN, where the vDNA remains in a vesicular compartment and a small portion of the L2
protein is accessible in the cytosol during transport for interactions with the host cell factors,
such as SNX17, SNX27, and retromer complex [30]. Retromer complex, which is involved
in the retrograde transport of different cargos, is critical for retrograde trafficking of the
HPV16 L2/vDNA cargo to the TGN (Figure 1) [81]. VAP dependent ER-endosome contact
might be involved in cleavage of virion containing vesicles and facilitating the trafficking
to the TGN, as extensive VAP dependent endosomal tabulation has been reported to be
induced by HPV-16 [82].
Cell cycle progression and subsequent nuclear envelope break down is another crucial
step in HPV infection [83,84]. Several groups demonstrated that the main restriction on
nuclear entry of the L2-vDNA complex and the initiation of viral gene expression is the
completion of mitosis [85,86]. The L2/vDNA complex therefore remains in the TGN until
it is transported to the nucleus [30]. After the onset of mitosis, the Golgi and TGN undergo
fragmentation and vesiculation, and L2/vDNA-containing vesicles then egress from the
TGN and associate with microtubules [30,87]. The vesicles migrate along the microtubules
towards the condensed chromosomes, where it has been suggested that the L2 protein
interacts with the chromosomes to ensure the L2/vDNA-containing vesicles remain at the
mitotic spindle [88]. Finally, L2/vDNA complex localize to punctate nuclear foci called
promyelocytic leukemia (PML) bodies, or ND10 (nuclear domain 10), in the interphase of
the infected cells [84,89], where the viral DNA transcription is believed to start.
Potential target sites preventing the entry process are indicated by red block arrows
with the inhibitory molecules described in detail in the text.
3. Molecular Targets of Early HPV Infection
The inability to propagate HPV in vitro has hampered research into the early stages
of HPV infection. However, by expressing the L1 protein using a number of eukaryotic
expression systems, it is possible for L1 to self-assemble into virus-like particles [38,90].
Co-expression of L1 and L2 along with a reporter gene to measure infection [91–93] has, for
example, led to the development of HPV pseudovirions (HPV-PsVs) which has been widely
used to study HPV entry mechanisms as well as to test potential inhibitory molecules
of HPV.
3.1. Targets of Heparan Sulfate Binding
The main objective in the development of microbicides against HPV (or any viral
infection) is to block the interaction between the virion proteins and the cell surface
receptors that are used by the virus to gain entry into the cells. As discussed previously,
initial HSPG binding is an important step to successful HPV internalization (Figure 1), as
its inhibition has shown to decrease HPV infection in vitro and in vivo [42,43,62]. Since
several different viruses use HS moieties as the initial receptor/coreceptor to bind to the
cell surface (see Section 2.1), it is considered a viable drug target, particularly with regards
to producing a microbicide that has broad spectrum protection against a number of HPVs
(as well as other sexually transmitted viruses).
3.1.1. Heparin and Heparin-Based Molecules
The interaction between HPV and HSPGs occurs between the basic amino acid
residues of viral proteins and the negatively charged sulfated/carboxyl groups of the
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GAG chains [48]. Because of this, heparin and other GAGs can competitively interfere
with virus attachment to cells [42,94,95]. Indeed, HPV11 VLPs were shown to interact
with heparin and with cell-surface GAGs in vitro, with high molecular weight heparin
inhibiting infection with a half maximal inhibition concentration (IC50) of 14.9 µM [95]. A
commercial low molecular weight heparin was also tested and was shown to have an IC50
of 762 µM [95]. Giroglou et al. confirmed that heparin also readily bound to HPV16 and 33-
PsVs, and the complete suppression of infection was observed at a heparin concentration of
2 µM (0.05 mg/mL) in vitro [42]. Other glycosaminoglycans, such as dermatan sulfate and
chondroitin sulfate, had no significant effect on HPV33-PsV infection [42]. Day et al. has
later shown that treatment of HPV16-PsVs with 10 µg/mL of soluble heparin prevented
cell surface association with HaCaT cells in vitro, resulting in an accumulation of the virus
on the ECM [96]. This again suggests that heparin acts as a competitive inhibitor that binds
to viral particles, blocking binding of the virions to surface HSPGs.
However, HPV’s sensitivity to heparin may differ depending on the HPV production
system used, as organotypic raft-culture derived HPV16 was found to attach to the cell
surface in the presence of heparin, while HPV18, 31 and 45 were unable to bind HaCaT
cells [97]. Although HPV 31 and 45 were unable to interact with the cell surface in the
presence of heparin, they were resistant to inhibition [97]. This has previously also been
seen for HPV31b infection of HaCaT cells [98] and suggests that under certain experimental
conditions, HPV16, 31 and 45 may attach to cells using a non-HS receptor, and that
different HPV types may utilize different molecules for initial attachment to the basement
membrane [97]. The discrepancy in the effect of heparin between organotypic derived or
pseudovirion production HPV particles may partly be explained by the presence of cellular
factors and proteases, which are necessary for infection (see Section 2.2.), being present in
the differentiating tissue culture, while being mostly absent from the pseudovirus system.
Even more surprising is a finding published by Cerqueira et al. in 2013, where prein-
cubation of HPV16-PsVs with increasing concentrations of heparin resulted in partial
restoration rather than more efficient inhibition of infection in vitro [99]. Moreover, interac-
tion of virions with heparin allowed HPV16-PsV infection in the absence of cell surface
HSPGs. From these findings, it seems as if heparin acted in lieu of HSPGs to allow even-
tual secondary receptor binding and internalization [99]. Therefore, there may not be an
absolute requirement for a specific HSPG receptor for HPV16, but rather specific glycan
moieties [99].
These studies warrant the research of modified heparin molecules or other heparin-
like molecules that have the same mechanism of action: binding to multiple HPV types
and preventing HSPG binding. Moreover, the effects of heparin in an in vivo model should
be explored for the different HPV types, as cell culture systems do not accurately mimic
the effects in a complex physiological and/or clinical context.
Research into drug delivery systems based on GAGs targeting viral infections led to
the development of spontaneously forming GAG-based nanoassemblies, in the hopes to
incorporate them into locally administered formulations to target viruses, to load antiviral
drugs, and to control their release over time [48]. The preparations of these spontaneous
nanoassemblies are formed in aqueous medium and do not require surfactants, pH modifi-
cation, or any heating and purification steps. In this process, nanoassemblies are obtained
by mixing a hydrophobically-modified polysaccharide and an α-cyclodextrin (α-CD). The
preparation of heparin-based nanoassemblies was achieved by the self-association of O-
palmitoyl-heparin (OPH) and α-CD. This resulted in the formation of well-structured
hexagonal-shaped nanoassemblies that could specifically bind and “trap” viruses and
avoid their attachment to GAGs on the cell surface [48]. The effect of the chemical modifi-
cation of OPH on antiviral activity was evaluated against HPV16-PsVs in vitro. The most
potent nanoassembly inhibited HPV16-PsVs with an IC50 of 1.25 µg/mL [48].
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3.1.2. Naturally Derived Sulfated Polysaccharides
Several high-molecular-weight sulfated/sulfonated polysaccharides or polymers have
been shown to have microbicidal activity against a number of sexually transmitted infec-
tions, such as HIV and HSV-1 and 2 [36,100–103]. Therefore, their microbicidal activity
against papillomaviruses has been assessed. Indeed, dextran sulfate (DS) and polystyrene
sulfate (PSS) showed strong inhibition of bovine papillomavirus (BPV), HPV11 and HPV40
in vitro with IC50 values ranging from 10 to 100 µg/mL [23]. Cellulose sulfate (CS), how-
ever, required greater concentrations to achieve virus inactivation (1000 µg/mL) [23]. The
authors proposed that DS and PSS achieved virus inactivation by binding to either the virus
or cell surface, thereby blocking virus attachment [23]. PSS, however, inhibited HPV11
infection even after the virus had attached to the cell surface. This result suggested that
blocking attachment to the cell surface may not be the exclusive mechanisms of inhibition
of these compounds [23].
Alginate, a soluble acidic polysaccharide found in brown seaweeds, composed of a
central backbone of poly-d-mannuronic acid (PM), poly-l-guluronic acid (PG), and alternate
residues of d-mannuronic acid and l-guluronic acid (PMG), was shown to significantly
inhibit HPV16- and HPV18-PsVs infection of HEK-293FT, HeLa and HaCaT cells, with IC50
values ranging between 0.7 and 3.3 µg/mL [104]. Further studies with HPV45-PsVs indi-
cated that PMGs may block the very early steps of the viral life cycle by directly associating
with the L1 protein [104]. Using a murine skin infection model, the researchers showed a
significant reduction in HPV45-PsVs infection when particles were pretreated with PMGs
(10 mg) or when PMGs were administered during infection. Inhibition by alginate has also
been documented for HIV, HSV and Hepatitis B virus (HBV), providing evidence for the
broad spectrum antiviral capabilities of brown seaweed-derived polysaccharides [105–107].
An important sulfated polysaccharide that has already entered clinical trials in the
prevention of HPV infection is carrageenan. It was first identified as a highly potent in-
hibitor of HPV6, 16, 18, 31 and 45-PsVs in 2006, using high-throughput screening [108].
The study showed that carrageenan treatment in the low ng/mL range resulted in 50%
inhibition [108]. Extracted from red algae, carrageenan has also been shown to inhibit HSV
and HIV infections in vitro [109]. The primary mode by which carrageenan blocks HPV
infection is by directly binding to the viral capsid, thereby blocking its interactions with
cell surface HSPG attachment factors [109]. Carrageenan was also shown to have an HSPG-
independent effect, either by blocking interactions with cellular proteins involved in the
internalization process or by preventing conformational changes to the capsid that are nec-
essary for infectious internalization [36]. However, depending on the experimental system
used, conflicting results are reported in the literature (see also Section 3.1.1.); while car-
rageenan was shown to be effective in inhibiting HPV18 and HPV31 native viral infections,
HPV16 and HPV45 could not be blocked by carrageenan, even at high carrageenan concen-
trations (100 mg/mL) [97]. These two HPV types are suggested to use GAG-independent
mechanisms to infect the host cell. Therefore, different carrageenan compounds/derivates
need to be considered for broad-spectrum antiviral activities against HPV.
Several groups explored the potential of carrageenan-based lubricants/microbicides in
inhibiting HPV infection [109]. A study by Roberts et al. proved carrageenan’s in vivo ap-
plication, where two commercial carrageenan-containing lubricants (Divine 9 and BIOglide)
decreased HPV16-PsV infection in a mouse model [36]. A separate study tested Divine
9 and the Population Council’s PC-515 gel against HPV16, 18, and 45-PsV infection in
a mouse model. Inhibition of infection was achieved for all HPV types tested, particu-
larly with PC-515, proving carrageenan’s broad-spectrum anti-HPV activity in vivo [110].
Novetsky et al. performed a phase I clinical study to evaluate the inhibition of HPV16-
PsV infection following the use of ‘Divine 9,’ a commercial 2% carrageenan-containing
lubricant [111]. The study involved the collection and testing of cervicovaginal lavages
in vitro in two groups of women without prior HPV vaccination or cervical intraepithelial
neoplasia. The first group was instructed to insert one dose of Divine 9 within 12 h before
vaginal intercourse; the second group was instructed to do the same but to additionally
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administer a second dose of gel as soon as possible after intercourse. Cervicovaginal lavage
(CVL) samples were combined with HPV16-PsVs to assess for inhibition of viral infection
in HEK-293TT cells. As a result, 93% of CVL samples showed HPV16-PsV inhibition
with a median of 97.5%, decreasing slightly over time [111]. Higher carrageenan concen-
trations were associated with higher HPV16-PsV inhibition [111]. In 2011, Marais et al.
reported a negative association of HPV infection with a vaginal 3% carrageenan-based
microbicide (Carraguard®), based on a phase III trial, comparing compliant Carraguard®
users and compliant placebo users [112]. Carrageenan was found to be associated with a
38% protective effect, but only among the most compliant participants. This randomized,
double-blind, placebo-controlled trial conducted in South Africa was originally designed
to assess the efficacy of a carrageenan-based gel in reducing the risk of HIV infection in
women, where the study did not show Carraguard®’s efficacy in the prevention of vaginal
transmission of HIV [112,113].
Two more recent clinical trials have been published in 2019, assessing the effective-
ness of carrageenan-based gels on HPV infection [114,115]. Magnan et al. conducted a
randomized, double-blind, placebo-controlled trial to assess the efficacy of a carrageenan-
based lubricant gel in reducing genital HPV incidence and prevalence among sexually
active women [114]. Two groups, one receiving the carrageenan lubricant and the other
a placebo lubricant, were instructed to self-apply inside the vagina and on the genital
area every second day for the first month and before and after each intercourse. The
carrageenan-based gel was associated with a 36% protective effect compared to the placebo,
thereby reducing the risk of both low and high oncogenic risk genital HPV infections in
women [114]. Perino et al. performed an observational study on the use of Carvir gel, a
new carrageenan/proprionibacterium extract-based vaginal microbicide [115]. This study
recruited 40 fertile females with genital HPV infections with (group A), or without (group
B) associated HPV-related low-risk genital lesions. Although the main outcome of the
report was to evaluate the safety and satisfaction of the use of the new gel, the authors
reported early findings on the rate of HPV genital infection clearance at the end of follow-
up in the intervention population, comparing these data with spontaneous clearance in a
control group. At the final follow-up visit, 60% of all patients had become HPV negative
(57.7% of group A; 64.3% of group B); among these, 13 cases were high-risk HPV infec-
tions. Patients treated with the carrageenan-based gel showed an HPV clearance five-times
higher (p = 0.005) than the control group [115]. The study, however, did not determine the
effectiveness of the carrageenan-based gel in the clearance of a specific papillomavirus
genotype [115].
3.1.3. Synthetic Sulfated Polysaccharides
It is argued that the use naturally derived sulfated polysaccharides for safe clinical
application faces a number of challenges, not the least of which is the possibility of spon-
taneous/alternative modifications in these natural compounds leading to heterogeneity
and impurities [108,116]. Most recently, the potential of highly sulfated glycomimetics
as inhibitors of HPV binding and infection has been assessed [116]. Glycomimetics are
synthetic glycan analogues which can even exceed the activities of the natural polysac-
charides from which they are derived [117]. These synthetic analogues have enhanced
stability, bioavailability, and half-life, making them ideal molecules to explore in their
capacity as antivirals.
Soria-Martinez et al. designed and synthesized both glycopolymers (long-chain) and
glycooligomers (short-chain) with a high degree of sulfation and a polymeric display of
saccharides (features shared with both heparin and carrageenan) [116]. Two different
glycopolymers were synthesized, one incorporating galactose side chains (PG1 and PG2)
and the other mannose side chains (PM). PG and PM had degrees of polymerization (dp)
of 40–44 and 86 respectively, and subsequently underwent sulfation. The pre-incubation of
HPV16-PsVs with either PG1 or PM abolished infection at 0.01 mg/mL in vitro, providing
evidence that a dp of 40 is enough to achieve maximal blocking efficacy. Their unsulfated
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counterparts could not inhibit infection. PM and PG1/2 exhibited IC50 values of 7 × 10−5
and 2 × 10−4 mg/mL respectively, which is as efficient as carrageenan and up to 100-fold
more efficient than heparin. The glycooligomers synthesized were much shorter than the
glycopolymers and GAGs. Overall, they were far less potent than the glycopolymers in
inhibiting HPV16-PsV infection, with an average IC50 of 0.1 mg/mL in vitro. Microscopic
analysis showed that glycopolymers blocked binding of HPV16-PsVs to cell surface HS.
Unexpectedly, glycooligomers allowed binding but not infection, suggesting a novel man-
ner in which these sulfated polymers can interfere with viral infection [116]. A mouse
vaginal challenge model was used to test the effectiveness of the oligopolymers in vivo.
PG2 was able to completely block infection in all mice, proving the in vivo antiviral effects
of sulfated glycopolymers [116].
3.1.4. Dispirotripiperazine
An alternative strategy to prevent virus binding to cellular HSPGs is the use of
compounds that interact with HS chains, thus competitively inhibiting virus attachment
(Figure 1). Dispirotripiperazine (DSTP), a class of low-molecular-weight antiherpetic
compounds, was shown to bind to heparin, preventing binding of viral particles to HS
moieties on the cell surface [118]. The N,N’-bisheteryl derivative of dispirotripiperazine,
DSTP27 has been reported by Selinka et al. to block HPV16 and 18-PsV infection over
an extended period of time, both pre- and post-binding of virions to the cell surface [62].
Firstly, it was reported that DSTP27 binds to cell surface HS preventing the initial binding
of virions to the cell surface. Secondly, DSTP27 was shown to prevent transfer from the
primary attachment receptor to a non-HSPG uptake receptor. DSTP27 efficiently blocked
HPV16 and 18-PsV infection of HEK 293TT cells with IC50 values of approximately 0.8
and 0.4 µg/mL respectively, and significantly reduced HPV infection for more than 30 h
post infection [62]. It was further proposed that in addition to the primary interaction of
HPV with HSPGs, the secondary interaction partners of HPV virions must also include
HSPG molecules, since both heparinase and DSTP27 prevented transfer from the primary
attachment receptor to a non-HSPG uptake receptor [62].
3.1.5. Polyethylenimines
Polyethylenimines (PEIs) are cationic polymers with known antimicrobial activ-
ity [119]. Given their polycationic nature, PEIs can condense with DNA, resulting in
PEI-DNA complexes which mediate HSPG-dependent gene transfer into mammalian cells
in vitro and in vivo [120]. Since PEIs interact with surface-expressed HSPGs, their potential
use as competitive HPV inhibitors was assessed [119]. Indeed, the infection efficiency
of HPV16-PsVs was significantly reduced by PEI in a concentration-dependent manner
in vitro, with 52nM PEI inhibiting HPV16-PsV infection by more than 99%. No cytotoxic
effects were exhibited at this concentration (CC50: 856.7 nM). Similar results were seen for
HPV-PsV types 18 and 31 across multiple cell lines. It was further confirmed that PEIs
affect the primary attachment of viral particles as PEI treatment almost completely blocked
viral attachment to the cell surface [119]. Importantly, PEI-mediated inhibition 24 h post
infection was maintained when administered more than 24 h before and up to 4 h after
addition of pseudovirions. This result suggests that PEI not only inhibits the binding
process of HPV16 but might also interfere with post binding events (Figure 1) [119].
3.1.6. Lactoferrin/Lactoferricin
Lactoferrin (LF), a monomeric glycoprotein found in secretions like saliva, breastmilk,
and semen, has important roles in host defense, and has been shown to inhibit a number of
fungi, bacteria, and viruses [121], such as HSV, HCMV, hepatitis C virus (HCV), poliovirus,
HIV, and HPV [122–126]. In 2004, Drobni et al. reported LF to act early in the HPV16
VLP uptake process, potentially on the receptor binding step, as the antiviral effect of LF
gradually disappeared in cells treated with HPV16 VLPs for increasing lengths of time
before LF treatment [127]. The study focused on both human derived LF (hLF) and bovine
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derived LF (bLF) and reported that bLF had the more potent inhibitory effect on HPV16
VLP uptake, with 50% inhibition at doses of 35 µg/mL [127]. A subsequent study showed
hLF and bLF had a strong inhibitory effect on HPV5- and HPV16-PsVs infection (IC50
values of 0.32 ± 0.18 µM and 0.25 ± 0.24 µM respectively) [128]. A number of human
and bovine lactoferricins (peptides released by lactoferrin pepsin digestion) have also
been shown to have antiviral activity [129]. A set of defined derivatives were analyzed,
where derivative bLfcin 17–3 showed the most potent inhibition of HPV5 and HPV16-PsV
infection in vitro, with IC50 values in the low µM range for all cell lines analyzed [128].
Glycosaminoglycan chains on the cell surface have been reported to interact with
LF [130], suggesting that LF binding to heparan sulfate blocks HPV receptor binding
(Figure 1). However, LF could also inhibit HPV uptake by directly binding to the virions,
as has been reported for poliovirus [131].
3.1.7. Dendrimers
Dendrimers are large, artificial, highly branched macromolecules synthesized from a
polyfunctional core. They can incorporate peptide bonds such as repeat units of polyamino
acids or polyethers that completely react with the functional groups of the core, in turn
leaving terminal functional groups that can react again [132]. Dendrimer molecules have
been synthesized to contain functional groups in the surface layer that can form complexes
with cell or viral receptors, disrupting normal virus-cell interactions, including the initial
binding of virus to the cell [132].
In an attempt to identify antiviral molecular antagonists of HSPGs, Donalisio et al.
screened a library of linear, dimeric, and dendrimeric peptides containing clusters of basic
amino acids that could bind to the negatively charged sulfate and carboxyl groups of
HS, thus inhibiting initial phases of HPV infection (Figure 1) [133]. SB105-A10 was one
such peptide which bound to the surfaces of two different epithelial cell lines, with EC50
values between 53 to 85 nM. Importantly, no cytotoxicity was observed [133]. In vitro
analysis identified SB105-A10 as a potent inhibitor of HPV-PsV types 16, 18 and 6, with
IC50s ranging between 0.59 and 0.88 µM. In addition, SB105-A10 retained its inhibitory
activity even when it was added to cell cultures 2 h after PsV infection, suggesting a
post-attachment inactivation mechanism [133]. The finding that SB105-A10 is active even
against multiple HPV types suggests a broad-spectrum capability of this molecule against
papillomaviruses. Besides its anti-HPV activity, SB105-A10 also proved active against
HIV-1 infection in vitro [133].
3.2. Targets of HPV Cellular Internalization
As mentioned previously, the exact mechanisms and host cellular receptors used by
HPV for successful internalization remain elusive. However, a few host cellular factors
that are involved in successful endocytosis of viral particles have been documented. Some
have been researched as potential targets of HPV infection [31,69].
3.2.1. Vimentin
Vimentin is a type II intermediate filament found in mammalian cells [134–136]. Vi-
mentin plays a role in a variety of cellular functions ranging from integrating into the entire
cytoskeleton, responding to mechanical stress, cellular adhesion, to signaling [137,138].
Although best described as a cytosolic protein involved in cellular processes such as cell
adhesion and cell migration, vimentin has been identified on the surface as well as in the
extracellular spaces of cells of various origins [139–142]. Many reports have been pub-
lished describing vimentin’s role in viral infection, with the majority showing vimentin’s
role in facilitating infectious internalization, such as Japanese encephalitis virus, Human
Cytomegalovirus and Enterovirus 71 [143–146].
In an attempt to identify key host molecules that interact with HPV16-PsVs, cell-
surface vimentin was identified as a novel HPV-binding molecule [41]. Surprisingly,
vimentin overexpression in multiple cell lines resulted in decreased levels of infection,
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while vimentin knockout by siRNA led to an increase in infection. Moreover, pre-incubation
of HPV16-PsVs with soluble recombinant human vimentin resulted in a decrease in viral
internalization by more than 50% in vitro. This suggested a vimentin-mediated blocking of
virus attachment and cellular entry, although the exact molecules involved in the vimentin-
mediated inhibition of HPV entry was not elucidated (Figure 1). However, infection as
measured by luciferase activity 48h later was not affected, possibly due to dissociation of the
vimentin-virus complexes [41]. The latter result warrants the exploration into stabilizing
the association of vimentin with viral particles in order for vimentin to exhibit prolonged
inhibition of HPV infection.
3.2.2. Anhydride-modified Protein (JB01)
Several groups have explored the ability of 3-hydroxyphthalic anhydride-modified
bovine beta-lactoglobulin, termed JB01, to potently inhibit HIV and HSV-1 and -2 [147–149].
In 2013, Lu et al. reported that this anhydride-modified protein can also inhibit the entry
of HPV in vitro [150]. JB01 showed potent inhibition of HPV-PsV types 6, 16 and 18, with
IC50 values of 0.33, 0.04, 0.065 mM, respectively [150]. Also, HPV58-PsV entry in vitro
was found to be inhibited by JB01 with an IC50 of 0.28 µg/mL [151]. Mechanistically, the
negatively charged regions on JB01 were shown to bind to the positively charged region of
the HPV L1 protein, and this interaction was proposed to competitively block the binding
of HPV to the receptor on the basement membrane in the vaginal mucosa (Figure 1) [151].
Importantly, the cytotoxicity of JB01 was determined to be insignificant in both human
cervical cells and vaginal epithelial cells, and could not be detected in the blood samples
of rhesus macaques, suggesting its safe use in a clinical setting [150]. In a randomized
clinical trial published in 2016, topical application of a vaginal gel containing JB01 showed
significant efficacy and safety in the treatment of high-risk HPV infections [152]. In this
study, women aged 25–65 years old infected by high-risk HPV, such as HPV types 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 were recruited. After 3 months of treatment, about
60.5% of HPV-positive women in the treatment group became HPV-negative compared
with 13.5% of women in the non-treatment group [152]. Importantly, JB01 was found to be
highly stable for up to 12 weeks, even at the human body temperature (37 ◦C) [150].
3.2.3. Annexin A2
As mentioned previously, annexin A2 facilitates infectious entry of HPV16 into ep-
ithelial cells [31]. HPV16 particles interact with annexin A2 in association with S100A10
as a heterotetramer at the cell surface in a calcium-dependent manner [69]. The annexin
A2/S100A10 heterotetramer (A2t) was shown to facilitate HPV16 entry through a direct
protein–protein interaction between the S100A10 subunit of A2t and the HPV16 L2 [153].
Woodham et al. saw this interaction as an opportunity to explore the effects of an annexin
A2 inhibitor, A2ti, on HPV16 infection in vitro [154]. Indeed, A2ti reduced HPV16-PsV
infection in HeLa and HaCaT cells in a dose dependent manner, with a 100% inhibition of
infection at 100 µM. Additionally, A2ti significantly decreased HPV16-PsV entry, with a
65% reduction at 100 µM. This result indicated that the inhibition of HPV16-PsV infection
with A2ti is due in part to a block in viral entry (Figure 1) [154].
3.2.4. Tetraspanin Blocking Peptides (CD63 and CD151)
A number of tetraspanins have been implicated in the successful entry of HPV particles
into target cells [31,67]. In 2018, Fast et al. determined which specific tetraspanin domains
were involved in HPV infection, particularly for CD63 and CD151 [67]. Of particular
interest was the C-terminal region, as this region facilitates complex formation between
CD63 and its direct interaction partner syntenin-1 [155], a requirement for post-endocytic
trafficking of HPV [73]. HPV infection also involves the C-terminus of CD151, as deletion
of this region causes CD151 to lose its activity with HPV16 [156]. Therefore, cytopermeable
peptides comprising the C-terminal region sequence of tetraspanin were assessed with
regard to their potential inhibitory functions. In vitro assays showed a dose dependent
Int. J. Mol. Sci. 2021, 22, 2201 13 of 26
decrease in HPV16-PsV infection in HeLa and HaCaT cells treated with the peptides (IC50
values ranging from 3.64 and 9.16 µM) [67]. A reduction in HCMV infection was also seen,
and it was proposed that these peptides may inhibit the entry of other viruses. Using
immunofluorescence assays, it was found that the CD63 and CD151 C-terminal peptides
decreased the disassembly of HPV16 capsids, which consequently inhibited infection,
and that the inhibitory effect of C-terminal CD63 and CD151 peptides occurs prior to
HPV capsid disassembly conforming to the role of CD63 and CD151 during HPV entry
(Figure 1) [67].
3.3. Targets of Intracellular Trafficking
Once internalized, endosomes containing HPV particles undergo maturation. The
formation of multivesicular bodies (MVBs) result in the sorting and subsequent disassembly
of the HPV capsid. This is followed by endosomal escape of the L2/vDNA complex, where
it is translocated to the host cell nucleus [30,157]. Factors regulating endosomal escape and
post-endocytosis trafficking of high-risk HPVs are also potential targets of HPV infection
and can be exploited to inhibit infection.
3.3.1. v-ATPase Inhibitors
Endosomal/lysosomal acidification is necessary for successful infection by a number
of viruses, including HPV [64,158]. Vacuolar ATPases (v-ATPases) which acidify the late
endosome by pumping protons across the endosomal membrane [159], were shown to
be required for successful HPV infection due to their role in the viral uncoating step
(Figure 1) [158]. Consequently, a number of different v-ATPase inhibitors were tested
for antiviral activity against HPV infections. Of those, Saliphenylhalamide (SaliPhe), a
derivative of the naturally occurring compound salicylihalamide, has proven to be a potent
inhibitor of mammalian v-ATPases [160]. SaliPhe was found to be an effective inhibitor
against HPV 6, 11, 16, 18 and 31-PsV infection in vitro, with 50% inhibition in the nM
range [158]. This was considered indicative of broad-spectrum anti-HPV activity of this
group of compounds.
3.3.2. Human α-Defensin 5
Using a high-throughput PsV-based screen, human α-defensin 5 (HD5) was identified
as a highly potent human innate antimicrobial peptide with inhibitory activity against gen-
ital HPV types 6, 16, 18, and 31, with similar IC50 values of approximately 0.6 µg/mL [161].
It was further suggested that HD5 blocks virion escape from endocytic vesicles but not
virion binding or internalization [161]. Indeed, Wiens and Smith showed that HD5 interacts
directly with HPV16-PsVs and inhibits the furin-mediated cleavage of L2 at the cell surface
during infection at a step downstream of the cyclophilin B-mediated unfolding of L2 [162],
thereby affecting endosomal escape. Interestingly, furin precleaved HPV16-PsVs were still
blocked by HD5, suggesting an additional mode of inhibition. HD5 was found to inhibit
HPV16-PsV infection by adversely affecting the dissociation of the major capsid protein
L1 and the viral genome which is critical for productive infection (Figure 1) [30]. HD5
treatment therefore dramatically changes the trafficking of the viral genome and capsid
proteins downstream of the early endosome, redirecting them away from the TGN and to
the lysosome. Based on these two studies, it is likely that the way in which HD5 interacts
with the capsid to block L2 cleavage also precludes the separation of L1 and L2 either by
maintaining overall capsid integrity or by stabilizing a subviral complex of L1, L2,and
genome [162].
3.3.2.1. γ-Secretase Inhibitors
The requirement of γ-secretase for successful infection is a unique feature of
HPVs [163,164]. γ-secretase is a transmembrane protease, which is involved in cleav-
age of transmembrane domains of numerous membrane proteins. Knockdown of any
of the four subunits leads to a potent block of HPV infection [163]. In 2010, Huang et al.
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showed that γ-secretase inhibitors (GSIs) inhibited the infectivity of HPV16-PsVs in human
keratinocytes at non-cytotoxic doses with IC50 in the picomolar to nanomolar range [165].
Similar results were seen for HPV11 and 31-PsVs. A strong inhibition of HPV infection was
observed also in the mouse model using topically-applied GSIs, suggesting that GSIs could
represent effective microbicides against anogenital HPVs [165]. Sensitivity to GSI was later
confirmed in diverse alpha and beta HPV types in vitro, with sensitivity greater than that of
furin inhibition [166]. Although the exact mechanism is unknown, it appears that inhibition
of γ-secretase activity results in a failure of L2/vDNA to reach the TGN (Figure 1), which
is consistent with the observation that HPV16 is only sensitive to γ-secretase inhibition
during the first 6–8 h of infection [164].
3.3.3. Stannin
Stannin, an 88-residue transmembrane protein, has been proposed to affect HPV16-
PsV infection in a similar manner to HD5. Using an overexpression genetic screen for
genes that affect HPV16-PsV infection, the SNN gene was identified that resulted in about
a 50% decrease in HPV5, 16 and 18-PsV infection in vitro [157]. Moreover, SNN deficient
mutant cell lines resulted in a 50% increase in HPV16-PsV infection to that of their wildtype
counterparts [157]. Further experiments showed that stannin does not affect virus uptake
or virus uncoating, but instead blocks virus entry into the TGN by routing the cargo
to lysosomal compartments for degradation. Stannin overexpression reduced L2 and
VPS35 co-localization, suggesting that it abrogates L2-retromer binding, a critical step for
L2/vDNA to enter the TGN (Figure 1) [30,157].
3.3.4. L2-Based Molecules
The L2 capsid protein has been implicated in participating in a series of downstream
subcellular trafficking events to ensure the nuclear delivery of the HPV genome. Therefore,
inhibiting intracellular virus trafficking by targeting L2 functions has been considered.
Yan et al. confirmed the importance of a highly conserved 36-amino-acid peptide sequence
of the L2 N terminus (L2N) for HPV infection [77]. This region contains the furin cleavage
sequence (RTKR) (17), an RG1/JWW-1 cross-type neutralization epitope with the conserved
cysteine residues for intramolecular disulfide bonds (17, 38), and a putative TM domain
adjacent to the glycine-rich GXXXG motif [79]. Indeed, ectopic expression of this L2N
terminal region on the cell surface greatly reduced HPV 16-PsV infection in various cell
lines [77]. Lipidation of the L2N peptide (creating L2N lipopeptides) successfully mimicked
the transmembrane domain function and blocked TGN trafficking of HPV, leading to
rapid virion degradation. As furin cleavage was necessary for the lipopeptides to inhibit
infection, it was speculated that the L2 N-terminal region interacts with a yet unknown
host membrane protein necessary for the successful endosomal escape of HPV particles.
Further research into L2 targeting peptides revealed that a peptide (P16/16) containing
the C-terminal region of HPV16 L2, spanning the L2 cell penetrating peptide (CPP) and the
adjacent retromer binding site (RBS)) not only inhibited HPV16-PsV infection, but HPV5
and 18-PsVs as well [167]. P16/16 was shown to enter cells from the culture medium and
bind retromer, thereby sequestering it from incoming HPV. This is proposed to prevent
endosome exit and trafficking of the incoming virus to the TGN, thereby aborting infection
(Figure 1) Moreover, P16/16 showed a decrease in infection in a mouse model with marginal
statistical significance (p = 0.088), proving that the peptide was not inactivated in the female
reproductive tract and can access basal keratinocytes in live tissue [167].
4. Conclusions
The current statistics on HPV and cervical cancer prevalence alone highlight the need
for alternative therapies for the prevention and treatment of HPV infections. The existing
HPV vaccines, although highly efficacious, do not provide protection against all the high-
risk HPV types, much less the low-risk HPV types. Furthermore, these vaccines are purely
prophylactic and are not easily accessible for women in LMIC. For these reasons, alternative
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therapies that have broad spectrum protection against HPV types, as well as other sexually
transmitted infections are worth exploring. Many LMIC countries, especially those in Sub
Saharan Africa are highly burdened with the HIV/AIDS pandemic, where co-infection
with HPV leads to accelerated and often more severe HPV-induced dysplasia and cancer
due to progressive immune suppression. Therefore, a microbicide capable of protecting
against HPV and HIV would be the most beneficial in an LMIC setting. Cost-effective
means of production and affordability by women in LMIC are also important aspects
to consider.
Targeting the early stages of viral entry is particularly promising and has been exten-
sively researched (Figure 1, Table 1). The knowledge of the viral particle components and
the host cell entry factors and their specific interactions can enable the design of efficient
antiviral strategies. One such target is inhibiting the initial attachment of viral particles to
the cell surface by either binding to the viral particle or by interacting with the attachment
receptor itself. The anti-HPV molecules that follow this mechanism of inhibition have also
been shown to inhibit other viral infections (Table 1). While it seems that most HPV and
other viruses use HSPGs during initial attachment to their target cells, the exact mecha-
nisms and conditions for successful attachment of the various virus (sub)types remain
speculative. Furthermore, the specific uptake receptors or receptor complexes used by HPV
subsequent to attachment are not known. This should not deter further research into the
molecules that target HPV in this manner, but rather promote further investigation.
We have already seen success in one such molecule, carrageenan, in reducing infection
in a clinical setting (Table 1). Carrageenan is already commercially produced and has the
potential to provide women a cost-effective protective alternative against HPV infection.
Carraguard®, a carrageenan-based microbicide, has shown to be safe to use. Unfortunately,
it has also been shown to be ineffective in protecting against HIV.
Many of the molecules targeting attachment detailed in this review have only been
tested with PsVs in vitro. Important to note are also the different approaches taken by
these studies, and how discrepancies in experimental design can yield different results.
For instance, the use of PsVs as opposed to native viral particles can yield conflicting
results. PsVs, although it has shed much light on the early steps of HPV infection, may not
provide the accurate picture needed to design highly effective inhibitors of HPV uptake
in vivo. Different HPVs may use different strategies to attach to and infect their host, as is
evident by some of the molecules described in this review having differential inhibition
amongst different HPV types. These are some of the few important factors to consider
when developing new agents to block HPV infections.
Furthermore, targeting downstream intracellular trafficking also looks promising,
where many of the molecules described in this review not only demonstrated inhibition of
HPV infections, but other sexually transmitted infections as well (Table 1). There is much
merit in researching molecules that target common stages of the viral life cycle, particularly
by targeting the virus–host interaction that are shared by most HPV types as well as other
infections such as HSV and HIV. However, efficient intracellular delivery is more difficult
to obtain compared to substances blocking viral attachment at the cell surface.
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The development of microbicides that contain one or a combination of the antiviral
molecules described here may provide many women with easily accessible protection
against sexually transmitted infections. Health care workers could be trained in the use
and importance of microbicides and can advocate microbicides for their ease of use. The
development of microbicides that can be sold over the counter (much like condoms) could
have a substantial impact against common STIs, especially if it were used by a significant
number of women. However, certain challenges might be anticipated in the development
and distribution of antiviral microbicides, not least of which is the production cost. To
maintain its affordability to women in an LMIC setting, the antiviral molecule production
system must be low cost and highly scalable so that it can be introduced and manufactured
in LMICs. These microbicides will need to be stabilized for storage for prolonged periods
at room temperature as cold storage is often inaccessible. Furthermore, it is important to
establish a sustainable supply of these microbicides before creating a demand for them.
Funding and successful clinical trials may also prove a challenge, which creates further
issues in establishing the safety and efficacy of these microbicides. If antiviral microbicides
reach the stage for safe use, the distribution of the microbicide as well as all the necessary
information must be appropriate for an LMIC setting. Women in LMIC may not have easy
access to distribution points for microbicides (and other methods of protection), nor the
necessary information on its use, safety and efficacy and appropriate hygiene standards
that should be implemented along with its use. Widespread access through a range of
distribution points (clinics, pharmacies, grocery stores) should be considered, together
with sexual and reproductive health education.
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